A new gene-expression risk model is being used to personalize allogeneic stem cell transplant decisions for children with AML, aiming to refine who benefits most from allo-HSCT. The approach integrates molecular risk signals tied to clinical outcomes, moving beyond broad clinicopathologic factors alone. The reported work frames allo-HSCT as a high-impact option that can improve survival but also carries serious risks such as graft-versus-host disease. By tailoring the decision with a risk model, clinicians can better balance benefit and harm for pediatric patients. For the pediatric hematology community, the development adds to a broader shift toward molecularly guided transplantation and risk stratification, potentially reducing overtreatment or underuse of transplant in specific biological subgroups.